Insider Buying: The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Just Bought US$1.6m Worth Of Shares

Those following along with Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) will no doubt be intrigued by the recent purchase of shares by insider Joseph Daly, who spent a stonking US$1.6m on stock at an average price of US$3.62. That purchase boosted their holding by 77%, which makes us wonder if the move was inspired by quietly confident deeply-felt optimism.

See our latest analysis for Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Joseph Daly was the biggest purchase of Brainstorm Cell Therapeutics shares made by an insider individual in the last twelve months, according to our records. So it’s clear an insider wanted to buy, at around the current price, which is US$3.92. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today’s share price, as the discount to value may have narrowed with the rising price. The good news for Brainstorm Cell Therapeutics share holders is that insiders were buying at near the current price. We note that Joseph Daly was also the biggest seller.

In the last twelve months insiders purchased 450876 shares for US$1.6m. But they sold 22038 for US$86k. In total, Brainstorm Cell Therapeutics insiders bought more than they sold over the last year. The chart below shows insider transactions (by individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqCM:BCLI Recent Insider Trading, November 23rd 2019
NasdaqCM:BCLI Recent Insider Trading, November 23rd 2019

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it’s a good sign if insiders own a significant number of shares in the company. Based on our data, Brainstorm Cell Therapeutics insiders have about 2.7% of the stock, worth approximately US$2.4m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. I generally like to see higher levels of ownership.

What Might The Insider Transactions At Brainstorm Cell Therapeutics Tell Us?

It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But we don’t feel the same about the fact the company is making losses. While the overall levels of insider ownership are below what we’d like to see, the history of transactions imply that Brainstorm Cell Therapeutics insiders are reasonably well aligned, and optimistic for the future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Brainstorm Cell Therapeutics.

If you would prefer to check out another company — one with potentially superior financials — then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you spot an error that warrants correction, please contact the editor at This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.